Project description
Flagellin aerosol therapy in treatment of drug-resistant bacterial pneumonia
Bacterial pneumonia is a leading cause of morbidity and mortality worldwide. Standard care with antibiotics is often complicated by antimicrobial resistance (AMR), resulting in curative failure. The EU-funded FAIR project aims to assess an adjunct to antibiotic therapy as an emerging concept to overcome AMR in pneumonia. The research focuses on the unique immunomodulator flagellin that enhances airway epithelial innate immune defences, and the development of airway-specific aerosol delivery by nebulisation. FAIR's main objectives include optimisation of nebulisation and demonstration of flagellin-associated enhancement of the antibiotic response, as well as obtaining pharmacokinetics and pharmacodynamics models for clinical validation and assessing flagellin nebulisation safety in a Phase I clinical trial.
Field of science
- /medical and health sciences/health sciences/public and environmental health
- /natural sciences/biological sciences/microbiology/bacteriology
- /medical and health sciences/basic medicine/pharmacology and pharmacy/drug resistance/antibiotic resistance
Programme(s)
Call for proposal
H2020-SC1-2019-Two-Stage-RTD
See other projects for this call
Funding Scheme
RIA - Research and Innovation actionCoordinator
75654 Paris
France
Participants (10)
75013 Paris
14195 Berlin
1228 Plan Les Ouates
H91 Galway
2300 Kobenhavn S
37044 Tours Cedex 9
1105AZ Amsterdam
59800 Lille
SO17 1BJ Southampton
1003 Lausanne